In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA).
The fluorometric microculture cytotoxicity assay (FMCA), a short-term in vitro assay based on the concept of total tumor cell kill, was used for testing the cytotoxic drug sensitivity of tumor cells from patients with ovarian carcinoma. A total of 125 fresh specimens was obtained, 98 (78%) of which were analyzed successfully. Data from 45 patients were available for clinical correlations. The FMCA appeared to yield clinically relevant cytotoxic drug sensitivity data for ovarian carcinoma as indicated by a comparison with tumor samples obtained from patients with non-Hodgkin's lymphoma or kidney carcinoma. Considering the most active single agent in vitro actually given in vivo, and using the median drug activity among all ovarian carcinoma samples as a cut-off, the sensitivity of the assay and its specificity were 75 and 52%, respectively. Cross-resistance in vitro was frequently observed between standard drugs but not between standard drugs and Taxol. Ten percent of the specimens showed an extreme resistance for at least 4 of 6 of the drugs investigated.
Csóka
K
K
Division of Clinical Pharmacology, University Hospital, Uppsala, Sweden. Csoka.Katalin@KlinFarm.uu.se
Tholander
B
B
Gerdin
E
E
de la Torre
M
M
Larsson
R
R
Nygren
P
P
D000970:Antineoplastic Agents / Q000633:toxicity*; D001706:Biopsy; D018929:Cell Culture Techniques / Q000379:methods; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D005260:Female; D005470:Fluorometry / Q000379:methods; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D011237:Predictive Value of Tests; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents